Atara Biotherapeutics Reports Exit/Disposal Costs
Ticker: ATRA · Form: 8-K · Filed: Oct 7, 2025 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | 8-K |
| Filed Date | Oct 7, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1.3 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: restructuring, disposal, 8-K
TL;DR
ATARA reporting exit/disposal costs - could mean restructuring.
AI Summary
On October 6, 2025, Atara Biotherapeutics, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing does not specify dollar amounts or exact dates for these costs, but indicates the reporting period ending October 6, 2025.
Why It Matters
This filing indicates potential restructuring or divestiture activities within Atara Biotherapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates costs associated with exit or disposal activities, suggesting potential business changes that carry inherent risks.
Key Players & Entities
- Atara Biotherapeutics, Inc. (company) — Registrant
- October 6, 2025 (date) — Date of earliest event reported
- 1280 Rancho Conejo Blvd (location) — Principal Executive Offices Address
- Thousand Oaks, California (location) — Principal Executive Offices City and State
- 91320 (location) — Principal Executive Offices Zip Code
FAQ
What specific activities are associated with the reported exit or disposal costs?
The filing does not specify the exact nature of the exit or disposal activities.
What is the total dollar amount of the costs associated with exit or disposal activities?
The filing does not disclose a specific dollar amount for these costs.
When did these exit or disposal activities commence?
The filing indicates the date of the earliest event reported as October 6, 2025, but does not provide prior commencement dates.
Has Atara Biotherapeutics undergone any recent restructuring or divestitures?
The filing suggests potential restructuring or divestitures through the reporting of exit or disposal costs, but does not explicitly confirm them.
What is the primary business of Atara Biotherapeutics, Inc.?
Atara Biotherapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances).
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 13.5 · Accepted 2025-10-06 17:32:17
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ATRA The Nasdaq Stock Mar
- $1.3 million — pany expects to recognize approximately $1.3 million for severance and related benefits for
Filing Documents
- d802811d8k.htm (8-K) — 22KB
- 0001193125-25-232117.txt ( ) — 129KB
- atra-20251006.xsd (EX-101.SCH) — 3KB
- atra-20251006_lab.xml (EX-101.LAB) — 17KB
- atra-20251006_pre.xml (EX-101.PRE) — 11KB
- d802811d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATARA BIOTHERAPEUTICS, INC. Date: October 6, 2025 By: /s/ AnhCo Thieu Nguyen AnhCo Thieu Nguyen President and Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer)